You are here

TissueGene awarded $750,000 Maryland Stem Cell Grant for Invossa™ Clinical Study

Primary tabs



The Maryland Stem Cell Research Fund (MSCRF) has awarded TissueGene Inc., a Maryland-based regenerative medicine company, a clinical grant for Invossa™, a cell and gene therapy for degenerative arthritis.

TissueGene was awarded the $750,000 grant from the Maryland Technology Development Corp. (TEDCO) via the MSCRF. The grant is to be used for conducting clinical trials in Maryland using cell therapy. This money is part of Accelerating Cure, a new TEDCO initiative to support regenerative medicine and cell therapy technologies in Maryland. 

The grant will be used by TissueGene to fund a component of a clinical study at a Maryland location for its U.S. Phase III clinical trial for Invossa™.  The goal of the study is to verify that Invossa™ exerts its therapeutic effect by tissue regeneration and on other inflammatory aspects of the disease such as synovitis.

Learn more: